The IGF axis has been implicated in acquired drug resistance in various hematologic cancers, and selective IGF-1 receptor inhibitors could block tumor cell proliferation and migration and overcome resistance to treatment of multiple myeloma, and lymphomas with bortezomib, EZH2 inhibitors and crizotinib 66–68. The gene discussed is IGF1; the disease is neoplasm.